# Genvax Technologies

Animal mRNA vaccines — self-amplifying mRNA (saRNA).

Source: https://en.bioecon.ru/companies/genvax-technologies/
Updated: 2026-06-25

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Production site | 10,000-square-foot manufacturing facility located at the Iowa State University Research Park in Ames, Iowa | https://www.econdev.iastate.edu/economic-development/impact-stories/19/genvax |
| Headcount | approximately 8 to 10 employees as of mid-2026 [medium confidence] | https://aeroleads.com/c/genvax, https://greyb.com/startups/genvax-technologies/ |
| Revenue | estimated annual revenue in the range of $1 million to $10 million as of mid-2026 [medium confidence] | https://greyb.com/startups/genvax-technologies/ |
| Regulatory approval | the company has made initial submissions to the USDA for product approvals, with the first product expected to launch in 2027 [medium confidence] | https://www.cultivationcorridor.org/news-events/applying-cutting-edge-technologies-to-develop-animal-vaccines |
| Certification | registered as a for-profit manufacturer of goods in the United States; primary NAICS code 325414 (Biological Product Manufacturing) | https://www.highergov.com/awardee/genvax-technologies-inc-12763537/ |

Independent sources: aeroleads.com, cultivationcorridor.org, econdev.iastate.edu, greyb.com, highergov.com

## Technologies

- [Veterinary biotech & mRNA veterinary drugs](https://en.bioecon.ru/technology/veterinary-biotech-mrna-drugs/)